ZW191 Shows Significant Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Data Highlights: ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% in platinum-resistant ovarian cancer patients, particularly excelling in FRα-positive individuals, indicating its potential to transform treatment paradigms for difficult-to-treat cancers.
- Survival Data: The median progression-free survival across all dose levels was reported at 7.6 months, suggesting a positive impact on extending patient survival, which further underscores the necessity for its clinical development.
- Tolerability Analysis: While 98% of patients experienced treatment-emergent adverse events (TEAEs), most were manageable, with 55% reporting grade 3 or higher events, indicating that ZW191's safety profile aligns with its promising clinical application.
- Dose Optimization Study Completion: The dose optimization phase of ZW191 has completed patient recruitment, with future development expected to inform dose selection between 6.4 mg/kg and 9.6 mg/kg, signaling a broad potential for clinical application.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZYME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.965
Low
30.00
Averages
35.55
High
42.00
Current: 22.965
Low
30.00
Averages
35.55
High
42.00
About ZYME
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ZW191 Shows Significant Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Patients
- Clinical Data Highlights: ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% in platinum-resistant ovarian cancer patients, particularly excelling in FRα-positive individuals, indicating its potential to transform treatment paradigms for difficult-to-treat cancers.
- Survival Data: The median progression-free survival across all dose levels was reported at 7.6 months, suggesting a positive impact on extending patient survival, which further underscores the necessity for its clinical development.
- Tolerability Analysis: While 98% of patients experienced treatment-emergent adverse events (TEAEs), most were manageable, with 55% reporting grade 3 or higher events, indicating that ZW191's safety profile aligns with its promising clinical application.
- Dose Optimization Study Completion: The dose optimization phase of ZW191 has completed patient recruitment, with future development expected to inform dose selection between 6.4 mg/kg and 9.6 mg/kg, signaling a broad potential for clinical application.
See More
Zymeworks to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zymeworks will participate in one-on-one meetings and a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 20, aiming to enhance investor interest in its multifunctional biotherapeutics pipeline.
- Innovation Summit Participation: The management will engage in a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, further showcasing its innovative capabilities and market potential in cancer treatment.
- Global Healthcare Conference: Zymeworks is set to attend the 2026 Jefferies Global Healthcare Conference on June 3 in New York, conducting one-on-one meetings and a fireside chat to attract more investor attention to its drug development progress.
- Strategic Partnerships and Product Development: Zymeworks is advancing its HER2-targeted bispecific antibody Ziihera through strategic collaborations with BeOne Medicines and Jazz Pharmaceuticals, demonstrating its strong competitive position in the biopharmaceutical sector.
See More
Zymeworks' ZW191 Shows Promising Efficacy in Phase 1 Trials
- Clinical Trial Results: Zymeworks presented Phase 1 data for ZW191 at the AACR Annual Meeting, achieving a confirmed objective response rate of 56% in platinum-resistant ovarian cancer patients, with 68% showing tumor regression and 94% disease control, indicating its potential in treating recurrent cancers.
- Targeting Specific Cancers: ZW191 is designed to target folate receptor alpha in ovarian and endometrial cancers, delivering a drug payload directly to tumor cells, addressing the urgent need for effective treatments in patients lacking options after standard therapies.
- Safety Profile: ZW191 demonstrated good tolerability at doses up to 11.2 mg/kg, with 55% of patients experiencing grade 3 or higher treatment-emergent adverse events, primarily neutropenia, anemia, and thrombocytopenia, while grade 4 events were rare, indicating a manageable safety profile.
- Next Steps in Research: The study's Part 2a has completed enrollment across North America, Europe, and Asia-Pacific, with results expected to guide the recommended dose for further registration studies, and ZW191's unique design positions it as a potential best-in-class therapy for gynecological cancers.
See More
Zymeworks Showcases Next-Generation ADC Programs at AACR 2026
- Next-Gen ADC Showcase: Zymeworks presented six posters at the AACR 2026 Annual Meeting, highlighting its antibody-drug conjugate (ADC) and payload development programs, emphasizing innovative potential in treating RAS-driven cancers.
- ZW191 Clinical Progress: ZW191, an FRα-targeting ADC, demonstrates favorable tolerability and efficacy when combined with standard therapies, supporting its further development in clinical stages.
- Targeted Innovations: Newly developed ADCs targeting Ly6E, CLDN18.2, and PTK7 show strong anti-tumor activity across various solid tumor models, potentially offering new treatment options for difficult-to-treat cancers.
- Future Outlook: Zymeworks plans to present updated clinical data on ZW191 during an oral presentation on April 21, 2026, further validating the efficacy and safety of its ADC platform and advancing the company's strategic development in the biotechnology sector.
See More
Zymeworks to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Zymeworks will report its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide investors with insights into the company's financial health and business progress.
- Conference Call Details: Following the earnings release, management will host a conference call and webcast at 4:30 PM ET on the same day to discuss financial results and provide corporate updates, enhancing transparency and investor confidence.
- Pipeline Development: Zymeworks is advancing its pipeline of multifunctional biotherapeutics, particularly innovative drugs targeting difficult-to-treat diseases like Ziihera®, indicating the company's ongoing innovation and competitiveness in the biotechnology sector.
- Strategic Partnerships: The company has entered exclusive development and commercialization agreements with BeOne Medicines and Jazz Pharmaceuticals, showcasing its strategic positioning and market expansion capabilities in the global biopharmaceutical landscape.
See More
Zymeworks Appoints New Heads of R&D and Business
- Executive Appointments: Zymeworks has officially appointed Dr. Adam Schayowitz as Head of R&D and Mr. Scott Platshon as Chief Business Officer as of April 9, 2026, aiming to enhance the company's execution and strategic positioning in the biotherapeutics sector.
- R&D Strategy: Dr. Schayowitz will leverage nearly two decades of oncology drug development experience to advance the clinical progression of the company's product candidates, particularly in areas of high unmet need, thereby enhancing the company's competitive edge in the market.
- Asset Management: Mr. Platshon is tasked with managing Zymeworks' asset aggregation strategy, which is expected to drive cash flows from products like Ziihera®, contributing to long-term shareholder value growth.
- Strategic Integration: These executive changes align with Zymeworks' overall strategy, aiming to optimize future cash flows and support ongoing investments in innovative therapeutics through the integration of R&D innovation and strategic collaborations.
See More
ZW191 Shows Significant Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Patients
- Clinical Data Highlights: ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% in platinum-resistant ovarian cancer patients, particularly excelling in FRα-positive individuals, indicating its potential to transform treatment paradigms for difficult-to-treat cancers.
- Survival Data: The median progression-free survival across all dose levels was reported at 7.6 months, suggesting a positive impact on extending patient survival, which further underscores the necessity for its clinical development.
- Tolerability Analysis: While 98% of patients experienced treatment-emergent adverse events (TEAEs), most were manageable, with 55% reporting grade 3 or higher events, indicating that ZW191's safety profile aligns with its promising clinical application.
- Dose Optimization Study Completion: The dose optimization phase of ZW191 has completed patient recruitment, with future development expected to inform dose selection between 6.4 mg/kg and 9.6 mg/kg, signaling a broad potential for clinical application.
See More
Zymeworks to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zymeworks will participate in one-on-one meetings and a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 20, aiming to enhance investor interest in its multifunctional biotherapeutics pipeline.
- Innovation Summit Participation: The management will engage in a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, further showcasing its innovative capabilities and market potential in cancer treatment.
- Global Healthcare Conference: Zymeworks is set to attend the 2026 Jefferies Global Healthcare Conference on June 3 in New York, conducting one-on-one meetings and a fireside chat to attract more investor attention to its drug development progress.
- Strategic Partnerships and Product Development: Zymeworks is advancing its HER2-targeted bispecific antibody Ziihera through strategic collaborations with BeOne Medicines and Jazz Pharmaceuticals, demonstrating its strong competitive position in the biopharmaceutical sector.
See More
Zymeworks' ZW191 Shows Promising Efficacy in Phase 1 Trials
- Clinical Trial Results: Zymeworks presented Phase 1 data for ZW191 at the AACR Annual Meeting, achieving a confirmed objective response rate of 56% in platinum-resistant ovarian cancer patients, with 68% showing tumor regression and 94% disease control, indicating its potential in treating recurrent cancers.
- Targeting Specific Cancers: ZW191 is designed to target folate receptor alpha in ovarian and endometrial cancers, delivering a drug payload directly to tumor cells, addressing the urgent need for effective treatments in patients lacking options after standard therapies.
- Safety Profile: ZW191 demonstrated good tolerability at doses up to 11.2 mg/kg, with 55% of patients experiencing grade 3 or higher treatment-emergent adverse events, primarily neutropenia, anemia, and thrombocytopenia, while grade 4 events were rare, indicating a manageable safety profile.
- Next Steps in Research: The study's Part 2a has completed enrollment across North America, Europe, and Asia-Pacific, with results expected to guide the recommended dose for further registration studies, and ZW191's unique design positions it as a potential best-in-class therapy for gynecological cancers.
See More
Zymeworks Showcases Next-Generation ADC Programs at AACR 2026
- Next-Gen ADC Showcase: Zymeworks presented six posters at the AACR 2026 Annual Meeting, highlighting its antibody-drug conjugate (ADC) and payload development programs, emphasizing innovative potential in treating RAS-driven cancers.
- ZW191 Clinical Progress: ZW191, an FRα-targeting ADC, demonstrates favorable tolerability and efficacy when combined with standard therapies, supporting its further development in clinical stages.
- Targeted Innovations: Newly developed ADCs targeting Ly6E, CLDN18.2, and PTK7 show strong anti-tumor activity across various solid tumor models, potentially offering new treatment options for difficult-to-treat cancers.
- Future Outlook: Zymeworks plans to present updated clinical data on ZW191 during an oral presentation on April 21, 2026, further validating the efficacy and safety of its ADC platform and advancing the company's strategic development in the biotechnology sector.
See More
Zymeworks to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Zymeworks will report its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide investors with insights into the company's financial health and business progress.
- Conference Call Details: Following the earnings release, management will host a conference call and webcast at 4:30 PM ET on the same day to discuss financial results and provide corporate updates, enhancing transparency and investor confidence.
- Pipeline Development: Zymeworks is advancing its pipeline of multifunctional biotherapeutics, particularly innovative drugs targeting difficult-to-treat diseases like Ziihera®, indicating the company's ongoing innovation and competitiveness in the biotechnology sector.
- Strategic Partnerships: The company has entered exclusive development and commercialization agreements with BeOne Medicines and Jazz Pharmaceuticals, showcasing its strategic positioning and market expansion capabilities in the global biopharmaceutical landscape.
See More
Zymeworks Appoints New Heads of R&D and Business
- Executive Appointments: Zymeworks has officially appointed Dr. Adam Schayowitz as Head of R&D and Mr. Scott Platshon as Chief Business Officer as of April 9, 2026, aiming to enhance the company's execution and strategic positioning in the biotherapeutics sector.
- R&D Strategy: Dr. Schayowitz will leverage nearly two decades of oncology drug development experience to advance the clinical progression of the company's product candidates, particularly in areas of high unmet need, thereby enhancing the company's competitive edge in the market.
- Asset Management: Mr. Platshon is tasked with managing Zymeworks' asset aggregation strategy, which is expected to drive cash flows from products like Ziihera®, contributing to long-term shareholder value growth.
- Strategic Integration: These executive changes align with Zymeworks' overall strategy, aiming to optimize future cash flows and support ongoing investments in innovative therapeutics through the integration of R&D innovation and strategic collaborations.
See More
